RNS Number : 4802Z
Genedrive PLC
15 May 2023

genedrive plc
("genedrive" or the "Company")

Block Listing Application to AIM

London, UK - 15 May 2023: genedrive plc (LSE: GDR), the point of care molecular diagnostics company, announces applications have been made to AIM for the admission to trading on the London Stock Exchange for the following block listings of Ordinary Shares of 1.5 pence each in the Company ("Ordinary Shares"):

- 2017 Share Option Scheme (1,150,588 Ordinary Shares)
- Unapproved Share Option Scheme (2,668,144 Ordinary Shares)

The Ordinary Shares may be issued from time to time for outstanding employee incentive vested share options not yet exercised. New Ordinary Shares issued following option exercises and admitted to trading under the block admission will rank *pari passu* in all respects with the existing Ordinary Shares.

The block listing is expected to become effective on 19 May 2023. The Company will make six-monthly announcements of the utilisation of the block admission, in line with its obligations under AIM Rule 29.

At the time of this announcement, Genedrive has 99,049,946 Ordinary Shares in issue. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information, please contact:

genedrive plc +44 (0) 161 989 0245
David Budd (Chief Executive Officer)
Russ Shaw (Chief Financial Officer)

Peel Hunt LLP - **Nominated Adviser, Joint Broker** +44 (0) 20 7148 8900
James Steel / Oliver Duckworth

finnCap Ltd - Joint Broker +44 (0) 20 7220 0500
Geoff Nash / George Dollemore

Walbrook PR - Financial PR & IR Adviser +44 (0) 20 7933 8780
Paul McManus / Anna Dunphy Or Genedrive@walbrookpr.com

About genedrive plc (http://www.genedriveplc.com)

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The company are currently developing a genetic test for CYP2C19 metaboliser status.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ALSQELFFXELEBBF